HPV and Survival in Esophageal Cancer Patients
Author Information
Author(s): Dreilich Martin, Bergqvist Michael, Moberg Martin, Brattström Daniel, Gustavsson Inger, Bergström Stefan, Wanders Alkwin, Hesselius Patrik, Wagenius Gunnar, Gyllensten Ulf
Primary Institution: Department of Oncology, University Hospital, Uppsala, Sweden
Hypothesis
What is the association between high-risk HPV types and survival rates in esophageal carcinoma patients?
Conclusion
HPV 16 did not influence survival or improve therapy response in esophageal carcinoma patients.
Supporting Evidence
- HPV 16 was detected in 16% of the patients.
- HPV 16 infection had no significant effect on survival.
- Median follow-up time was 297 days.
Takeaway
The study looked at whether a virus called HPV affects how long people with esophageal cancer live. It found that HPV didn't help them live longer or respond better to treatment.
Methodology
The study used real-time PCR to detect HPV types in tumor samples from patients and analyzed survival data.
Limitations
The study had a small sample size and was a pilot study, indicating a need for further research.
Participant Demographics
Patients were from the Department of Oncology, Uppsala Hospital, Sweden, with a mix of genders and ages.
Statistical Information
P-Value
0.72
Statistical Significance
p = 0.72
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website